Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 797

1.

Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning.

Franzmeier N, Koutsouleris N, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Duering M, Dichgans M, Levin J, Gordon BA, Lim YY, Masters CL, Rossor M, Fox NC, O'Connor A, Chhatwal J, Salloway S, Danek A, Hassenstab J, Schofield PR, Morris JC, Bateman RJ; Alzheimer's disease neuroimaging initiative (ADNI); Dominantly Inherited Alzheimer Network (DIAN), Ewers M.

Alzheimers Dement. 2020 Feb 11. doi: 10.1002/alz.12032. [Epub ahead of print]

PMID:
32043733
2.

Optimizing red blood cell protein extraction for biomarker quantitation with mass spectrometry.

Klatt S, Roberts A, Lothian A, Masters CL, Cappai R, Fowler C, Roberts BR.

Anal Bioanal Chem. 2020 Feb 6. doi: 10.1007/s00216-020-02439-5. [Epub ahead of print]

PMID:
32030493
3.

Relationship of Established Cardiovascular Risk Factors and Peripheral Biomarkers on Cognitive Function in Adults at Risk of Cognitive Deterioration.

Lai MMY, Sharman MJ, Ames DJ, Ellis KA, Cox KL, Hepworth G, Desmond P, Cyarto EV, Martins RN, Masters CL, Lautenschlager NT.

J Alzheimers Dis. 2020 Jan 28. doi: 10.3233/JAD-190953. [Epub ahead of print]

PMID:
32007955
4.

Rates of age- and amyloid β-associated cortical atrophy in older adults with superior memory performance.

Dang C, Yassi N, Harrington KD, Xia Y, Lim YY, Ames D, Laws SM, Hickey M, Rainey-Smith S, Sohrabi HR, Doecke JD, Fripp J, Salvado O, Snyder PJ, Weinborn M, Villemagne VL, Rowe CC, Masters CL, Maruff P; AIBL Research Group.

Alzheimers Dement (Amst). 2019 Aug 12;11:566-575. doi: 10.1016/j.dadm.2019.05.005. eCollection 2019 Dec.

5.

Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer's Disease.

Yassi N, Hilal S, Xia Y, Lim YY, Watson R, Kuijf H, Fowler C, Yates P, Maruff P, Martins R, Ames D, Chen C, Rowe CC, Villemagne VL, Salvado O, Desmond PM, Masters CL.

J Alzheimers Dis. 2020;73(3):897-907. doi: 10.3233/JAD-191028.

PMID:
31884485
6.

Cerebrospinal fluid neurofilament light chain is elevated in Niemann-Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response.

Eratne D, Loi SM, Li QX, Varghese S, McGlade A, Collins S, Masters CL, Velakoulis D, Walterfang M.

Aust N Z J Psychiatry. 2019 Dec 11:4867419893431. doi: 10.1177/0004867419893431. [Epub ahead of print] No abstract available.

PMID:
31823653
7.

Harmonization of large MRI datasets for the analysis of brain imaging patterns throughout the lifespan.

Pomponio R, Erus G, Habes M, Doshi J, Srinivasan D, Mamourian E, Bashyam V, Nasrallah IM, Satterthwaite TD, Fan Y, Launer LJ, Masters CL, Maruff P, Zhuo C, Völzke H, Johnson SC, Fripp J, Koutsouleris N, Wolf DH, Gur R, Gur R, Morris J, Albert MS, Grabe HJ, Resnick SM, Bryan RN, Wolk DA, Shinohara RT, Shou H, Davatzikos C.

Neuroimage. 2020 Mar;208:116450. doi: 10.1016/j.neuroimage.2019.116450. Epub 2019 Dec 9.

8.

Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD.

Papp KV, Buckley R, Mormino E, Maruff P, Villemagne VL, Masters CL, Johnson KA, Rentz DM, Sperling RA, Amariglio RE; Collaborators from the Harvard Aging Brain Study, the Alzheimer's Disease Neuroimaging Initiative and the Australian Imaging, Biomarker and Lifestyle Study of Aging.

Alzheimers Dement. 2019 Nov 20. pii: S1552-5260(19)35446-9. doi: 10.1016/j.jalz.2019.09.074. [Epub ahead of print]

9.

Decrease in p3-Alcβ37 and p3-Alcβ40, products of Alcadein β generated by γ-secretase cleavages, in aged monkeys and patients with Alzheimer's disease.

Hata S, Omori C, Kimura A, Saito H, Kimura N, Gupta V, Pedrini S, Hone E, Chatterjee P, Taddei K, Kasuga K, Ikeuchi T, Waragai M, Nishimura M, Hu A, Nakaya T, Meijer L, Maeda M, Yamamoto T, Masters CL, Rowe CC, Ames D, Yamamoto K, Martins RN, Gandy S, Suzuki T.

Alzheimers Dement (N Y). 2019 Nov 7;5:740-750. doi: 10.1016/j.trci.2019.09.015. eCollection 2019.

10.

Validation of a priori candidate Alzheimer's disease SNPs with brain amyloid-beta deposition.

Vacher M, Porter T, Villemagne VL, Milicic L, Peretti M, Fowler C, Martins R, Rainey-Smith S, Ames D, Masters CL, Rowe CC, Doecke JD, Laws SM.

Sci Rep. 2019 Nov 19;9(1):17069. doi: 10.1038/s41598-019-53604-5.

11.

Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.

Burnham SC, Coloma PM, Li QX, Collins S, Savage G, Laws S, Doecke J, Maruff P, Martins RN, Ames D, Rowe CC, Masters CL, Villemagne VL.

J Prev Alzheimers Dis. 2019;6(4):248-255. doi: 10.14283/jpad.2019.25.

PMID:
31686097
12.

Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study.

Buckley RF, Sikkes S, Villemagne VL, Mormino EC, Rabin JS, Burnham S, Papp KV, Doré V, Masters CL, Properzi MJ, Schultz AP, Johnson KA, Rentz DM, Sperling RA, Amariglio RE.

Alzheimers Dement (Amst). 2019 Sep 25;11:670-678. doi: 10.1016/j.dadm.2019.08.004. eCollection 2019 Dec.

13.

An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations.

Dube U, Del-Aguila JL, Li Z, Budde JP, Jiang S, Hsu S, Ibanez L, Fernandez MV, Farias F, Norton J, Gentsch J, Wang F; Dominantly Inherited Alzheimer Network (DIAN), Salloway S, Masters CL, Lee JH, Graff-Radford NR, Chhatwal JP, Bateman RJ, Morris JC, Karch CM, Harari O, Cruchaga C.

Nat Neurosci. 2019 Nov;22(11):1903-1912. doi: 10.1038/s41593-019-0501-5. Epub 2019 Oct 7.

PMID:
31591557
14.

Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.

Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P.

Nat Commun. 2019 Sep 17;10(1):4227. doi: 10.1038/s41467-019-12242-1.

15.

The dawn of robust individualised risk models for dementia.

Burnham SC, Loi SM, Doecke J, Fedyashov V, Dore V, Villemagne VL, Masters CL.

Lancet Neurol. 2019 Nov;18(11):985-987. doi: 10.1016/S1474-4422(19)30353-9. Epub 2019 Sep 13. No abstract available.

PMID:
31526626
16.

Use of an experimental language acquisition paradigm for standardized neuropsychological assessment of learning: A pilot study in young and older adults.

Baker JE, Bruns L Jr, Hassenstab J, Masters CL, Maruff P, Lim YY.

J Clin Exp Neuropsychol. 2020 Feb;42(1):55-65. doi: 10.1080/13803395.2019.1665626. Epub 2019 Sep 13.

PMID:
31514573
17.

Genetic resilience to Alzheimer's disease in APOE ε4 homozygotes: A systematic review.

Huq AJ, Fransquet P, Laws SM, Ryan J, Sebra R, Masters CL, Winship IM, James PA, Lacaze P.

Alzheimers Dement. 2019 Dec;15(12):1612-1623. doi: 10.1016/j.jalz.2019.05.011. Epub 2019 Sep 7.

PMID:
31506248
18.

A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials.

Xiong C, Luo J, Agboola F, Li Y, Albert M, Johnson SC, Koscik RL, Masters CL, Soldan A, Villemagne VL, Li QX, McDade EM, Fagan AM, Massoumzadeh P, Benzinger T, Hassenstab J, Bateman RJ, Morris JC; Dominantly Inherited Alzheimer Network.

Alzheimers Dement. 2019 Nov;15(11):1448-1457. doi: 10.1016/j.jalz.2019.06.4955. Epub 2019 Sep 7.

PMID:
31506247
19.

Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults.

Baker JE, Pietrzak RH, Laws SM, Ames D, Villemagne VL, Rowe CC, Masters CL, Maruff P, Lim YY.

Neuropsychology. 2019 Oct;33(7):964-974. doi: 10.1037/neu0000561. Epub 2019 Aug 1.

PMID:
31368758
20.

Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial.

Venkatraman VK, Sanderson A, Cox KL, Ellis KA, Steward C, Phal PM, Gorelik A, Sharman MJ, Villemagne VL, Lai M, Cyarto EV, Merkel B, Ames D, Szoeke C, Rowe CC, Masters CL, Lautenschlager NT, Desmond PM.

Neurobiol Aging. 2019 May 27. pii: S0197-4580(19)30155-1. doi: 10.1016/j.neurobiolaging.2019.02.030. [Epub ahead of print]

PMID:
31324405
21.

Determining clinically meaningful decline in preclinical Alzheimer disease.

Insel PS, Weiner M, Mackin RS, Mormino E, Lim YY, Stomrud E, Palmqvist S, Masters CL, Maruff PT, Hansson O, Mattsson N.

Neurology. 2019 Jul 23;93(4):e322-e333. doi: 10.1212/WNL.0000000000007831. Epub 2019 Jul 9.

22.

A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?

Eratne D, Loi SM, Walia N, Farrand S, Li QX, Varghese S, Walterfang M, Evans A, Mocellin R, Dhiman K, Gupta V, Malpas CB, Collins S, Masters CL, Velakoulis D.

Aust N Z J Psychiatry. 2020 Jan;54(1):57-67. doi: 10.1177/0004867419857811. Epub 2019 Jun 21.

PMID:
31220922
23.

Avoiding methodological bias in studies of amyloid imaging results disclosure.

Taswell C, Donohue C, Mastwyk MT, Louey AG, Giummarra J, Robertson J, Darby DG, Masters CL, Rowe CC.

Alzheimers Res Ther. 2019 Jun 4;11(1):52. doi: 10.1186/s13195-019-0495-y. No abstract available.

24.

Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer's disease.

Fazlollahi A, Calamante F, Liang X, Bourgeat P, Raniga P, Dore V, Fripp J, Ames D, Masters CL, Rowe CC, Connelly A, Villemagne VL, Salvado O; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group.

J Magn Reson Imaging. 2020 Feb;51(2):505-513. doi: 10.1002/jmri.26810. Epub 2019 May 30.

PMID:
31145515
25.

Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.

Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, Rutz S, Widmann M, Leinenbach A, Blennow K.

Clin Biochem. 2019 Oct;72:7-14. doi: 10.1016/j.clinbiochem.2019.05.006. Epub 2019 May 23.

26.

Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: Validation against histopathology.

Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, Stephens AW, Barthel H, Fripp J, Masters CL, Dinkelborg L, Salvado O, Villemagne VL, De Santi S.

Alzheimers Dement. 2019 Jun;15(6):807-816. doi: 10.1016/j.jalz.2019.02.005. Epub 2019 May 14.

PMID:
31101517
27.

COMT val158met is not associated with Aβ-amyloid and APOE ε4 related cognitive decline in cognitively normal older adults.

Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Sohrabi HR, Peretti M, Lim YY, Weinborn M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM.

IBRO Rep. 2019 May 2;6:147-152. doi: 10.1016/j.ibror.2019.05.001. eCollection 2019 Jun.

28.

Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.

Bransby L, Lim YY, Ames D, Fowler C, Roberston J, Harrington K, Snyder PJ, Villemagne VL, Salvado O, Masters CL, Maruff P for the AIBL Research Group.

J Clin Exp Neuropsychol. 2019 Aug;41(6):591-600. doi: 10.1080/13803395.2019.1593949. Epub 2019 Mar 29.

PMID:
30924399
29.

The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease.

Franzmeier N, Ren J, Damm A, Monté-Rubio G, Boada M, Ruiz A, Ramirez A, Jessen F, Düzel E, Rodríguez Gómez O, Benzinger T, Goate A, Karch CM, Fagan AM, McDade E, Buerger K, Levin J, Duering M, Dichgans M, Suárez-Calvet M, Haass C, Gordon BA, Lim YY, Masters CL, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Milz E, Moreno-Grau S, Teipel S, Grothe MJ, Kilimann I, Rossor M, Fox N, Laske C, Chhatwal J, Falkai P, Perneczky R, Lee JH, Spottke A, Boecker H, Brosseron F, Fliessbach K, Heneka MT, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Salloway S, Danek A, Hassenstab J, Yakushev I, Schofield PR, Morris JC, Bateman RJ, Ewers M.

Mol Psychiatry. 2019 Mar 21. doi: 10.1038/s41380-019-0404-6. [Epub ahead of print]

30.

Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.

Vöglein J, Paumier K, Jucker M, Preische O, McDade E, Hassenstab J, Benzinger TL, Noble JM, Berman SB, Graff-Radford NR, Ghetti B, Farlow MR, Chhatwal J, Salloway S, Xiong C, Karch CM, Cairns N, Mori H, Schofield PR, Masters CL, Goate A, Buckles V, Fox N, Rossor M, Chrem P, Allegri R, Ringman JM, Höglinger G, Steiner H, Dieterich M, Haass C, Laske C, Morris JC, Bateman RJ, Danek A, Levin J; Dominantly Inherited Alzheimer Network.

Brain. 2019 May 1;142(5):1429-1440. doi: 10.1093/brain/awz050.

PMID:
30897203
31.

Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies.

Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR Jr, Farlow MR, Salloway S, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS.

Alzheimers Dement (Amst). 2019 Feb 22;11:180-190. doi: 10.1016/j.dadm.2018.12.008. eCollection 2019 Dec.

32.

ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes.

Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, Li QX, Collins SJ, Carlsson C, Asthana S, Masters CL, Johnson S, Morris JC, Albert M, Gross AL.

Neurology. 2019 Apr 2;92(14):e1567-e1579. doi: 10.1212/WNL.0000000000007248. Epub 2019 Mar 6.

PMID:
30842300
33.

To What Extent Does Age at Death Account for Sex Differences in Rates of Mortality From Alzheimer Disease?

Buckley RF, Waller M, Masters CL, Dobson A.

Am J Epidemiol. 2019 Jul 1;188(7):1213-1223. doi: 10.1093/aje/kwz048.

PMID:
30824901
34.

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease.

Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Aarsland D, Powell J, Lovestone S, Martins R, Hye A.

Sci Adv. 2019 Feb 6;5(2):eaau7220. doi: 10.1126/sciadv.aau7220. eCollection 2019 Feb.

35.

Klotho allele status is not associated with Aβ and APOE ε4-related cognitive decline in preclinical Alzheimer's disease.

Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM.

Neurobiol Aging. 2019 Apr;76:162-165. doi: 10.1016/j.neurobiolaging.2018.12.014. Epub 2019 Jan 6.

PMID:
30716541
36.

Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study.

Villemagne VL, Velakoulis D, Doré V, Bozinoski S, Masters CL, Rowe CC, Walterfang M.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1132-1138. doi: 10.1007/s00259-019-4273-7. Epub 2019 Jan 28.

PMID:
30690666
37.

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.

Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M; Dominantly Inherited Alzheimer Network.

Nat Med. 2019 Feb;25(2):277-283. doi: 10.1038/s41591-018-0304-3. Epub 2019 Jan 21.

38.

Creutzfeldt-Jakob disease surveillance in Australia: update to December 2016.

Klug GM, Sarros S, Stehmann C, Simpson M, McLean C, Masters CL, Collins SJ.

Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00023-4. Epub 2018 Dec 17.

39.

A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease.

Porter T, Burnham SC, Savage G, Lim YY, Maruff P, Milicic L, Peretti M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Taddei K, Groth D, Verdile G, Villemagne VL, Laws SM.

Front Aging Neurosci. 2018 Dec 19;10:423. doi: 10.3389/fnagi.2018.00423. eCollection 2018.

40.

Seizures as an early symptom of autosomal dominant Alzheimer's disease.

Vöglein J, Noachtar S, McDade E, Quaid KA, Salloway S, Ghetti B, Noble J, Berman S, Chhatwal J, Mori H, Fox N, Allegri R, Masters CL, Buckles V, Ringman JM, Rossor M, Schofield PR, Sperling R, Jucker M, Laske C, Paumier K, Morris JC, Bateman RJ, Levin J, Danek A; Dominantly Inherited Alzheimer Network.

Neurobiol Aging. 2019 Apr;76:18-23. doi: 10.1016/j.neurobiolaging.2018.11.022. Epub 2018 Dec 5.

PMID:
30616208
41.

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.

Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, Karch CM, Cruchaga C, Paumier K, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Jucker M, Masters CL, Rossor MN, Ringman JM, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Dominantly Inherited Alzheimer Network; Alzheimer's Disease Neuroimaging Initiative.

EMBO Mol Med. 2018 Dec;10(12). pii: e9712. doi: 10.15252/emmm.201809712.

42.

Characterization of the metal status of natively purified alpha-synuclein from human blood, brain tissue, or recombinant sources using size exclusion ICP-MS reveals no significant binding of Cu, Fe or Zn.

Lothian A, Lago L, Mukherjee S, Connor AR, Fowler C, McLean CA, Horne M, Masters CL, Cappai R, Roberts BR.

Metallomics. 2019 Jan 23;11(1):128-140. doi: 10.1039/c8mt00223a.

PMID:
30465671
43.

Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.

Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Li QX, Ames D, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM; AIBL Research Group.

J Alzheimers Dis. 2018;66(3):1193-1211. doi: 10.3233/JAD-180713.

PMID:
30412495
44.

Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing.

Rainey-Smith SR, Gu Y, Gardener SL, Doecke JD, Villemagne VL, Brown BM, Taddei K, Laws SM, Sohrabi HR, Weinborn M, Ames D, Fowler C, Macaulay SL, Maruff P, Masters CL, Salvado O, Rowe CC, Scarmeas N, Martins RN.

Transl Psychiatry. 2018 Oct 30;8(1):238. doi: 10.1038/s41398-018-0293-5.

45.

A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimer's Disease: The AIBL Active-Study.

Cox KL, Cyarto EV, Ellis KA, Ames D, Desmond P, Phal P, Sharman MJ, Szoeke C, Rowe CC, Masters CL, You E, Burrows S, Lai MMY, Lautenschlager NT.

J Alzheimers Dis. 2019;70(s1):S187-S205. doi: 10.3233/JAD-180521.

46.

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.

La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Doré V, Grinberg LT, Huang E, Hwang JH, Ikonomovic MD, Jack C Jr, Jagust WJ, Jin LW, Klunk WE, Kofler J, Lesman-Segev OH, Lockhart SN, Lowe VJ, Masters CL, Mathis CA, McLean CL, Miller BL, Mungas D, O'Neil JP, Olichney JM, Parisi JE, Petersen RC, Rosen HJ, Rowe CC, Spina S, Vemuri P, Villemagne VL, Murray ME, Rabinovici GD.

Alzheimers Dement. 2019 Feb;15(2):205-216. doi: 10.1016/j.jalz.2018.09.001. Epub 2018 Oct 19.

47.

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.

Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, Kiddle SJ, Batrla R, Blennow K.

Nat Rev Neurol. 2018 Nov;14(11):639-652. doi: 10.1038/s41582-018-0079-7. Review.

48.

Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults.

Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith SR, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P; AIBL Research Group.

Arch Clin Neuropsychol. 2019 Jul 26;34(5):585-598. doi: 10.1093/arclin/acy078.

PMID:
30272115
49.

Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease.

Müller S, Preische O, Sohrabi HR, Gräber S, Jucker M, Ringman JM, Martins RN, McDade E, Schofield PR, Ghetti B, Rossor M, Fox NN, Graff-Radford NR, Levin J, Danek A, Vöglein J, Salloway S, Xiong C, Benzinger T, Buckles V, Masters CL, Sperling R, Bateman RJ, Morris JC, Laske C; Dominantly Inherited Alzheimer Network (DIAN).

Alzheimers Dement. 2018 Nov;14(11):1427-1437. doi: 10.1016/j.jalz.2018.06.3059. Epub 2018 Sep 25.

50.

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease.

Araque Caballero MÁ, Suárez-Calvet M, Duering M, Franzmeier N, Benzinger T, Fagan AM, Bateman RJ, Jack CR, Levin J, Dichgans M, Jucker M, Karch C, Masters CL, Morris JC, Weiner M, Rossor M, Fox NC, Lee JH, Salloway S, Danek A, Goate A, Yakushev I, Hassenstab J, Schofield PR, Haass C, Ewers M.

Brain. 2018 Oct 1;141(10):3065-3080. doi: 10.1093/brain/awy229.

Supplemental Content

Loading ...
Support Center